Search

The design, analysis, and test of the integrated device for the launch adapter and the resettable orbital deployer are presented in this paper. This integrated device contains both functions of the single-use launch adapter and the resettable orbital deployer. Two types of release mechanisms are combined. The four-bar linkage mechanism is applied in the single-use adapter function. This release mechanism provides sufficient strength of connection in the launch stage and is released when entering the orbit. The electromagnetic hook mechanism is applied in the resettable orbital deployer. The deployer can be reloaded by the manipulator on the mother satellite with picosatellites taken out from the cargo to deploy multiple times. Dynamics simulation, finite element simulation, as well as the prototype test verify the preliminary feasibility of this design. [ABSTRACT FROM AUTHOR]

RNA targeting the murine vascular endothelial growth factor receptor 2 (VEGFR2) gene was designed and validated for efficient and robust silencing in vitro and was delivered by polyethylenimines (PEI) in vivo to investigate the antitumor effect on non-small cell lung cancer (NSCLC) xenografts. The following dosage regimens were tested for their tumor inhibitory effect in vivo: VEGFR2 siRNA, epidermal growth factor receptor (EGFR) siRNA, VEGFR2 siRNA+EGFR siRNA, cisplatin alone and VEGFR2 siRNA+ EGFR siRNA+cisplatin. Targeted silencing of both VEGFR2 and EGFR expression by siRNA, combined with low-dose cisplatin, was found to effectively inhibit tumor growth and extend the survival time of mice bearing the NSCLC xenografts. These results suggest that combination therapy using siRNAs and chemotherapy agents might offer a novel strategy for cancer treatment in the future.